抗体药物研发解决方案

概述

抗体药物研发解决方案

斯达特生物提供抗体药物研发全流程解决方案，依托单 B 细胞抗体开发、重组蛋白表达、抗体工程与多平台验证体系，覆盖抗原设计、免疫、筛选、表达、纯化及功能验证，支持单抗、双抗、ADC、IVD 原料等研发需求，为肿瘤、免疫、感染、神经等疾病领域提供高特异性、高亲和力抗体工具与定制开发服务。

概述

相关文献

A novel FTO-targeting nanodrug induces disulfidptosis and ameliorates the suppressive tumor immune environment to treat uveal melanoma

杂志名称： Biomaterials

作者： Hao Tian; Hongpei Deng; Xinlong Liu; Chang Liu; Chuan Zhang; Kam W. Leong; Jing Ruan; Xianqun Fan

IF: 12.8

Ascorbic Acid-Derived Supramolecular Gels Induce Immunogenic Ferroptosis in Cancer Cells to Potentiate Tumor Immunotherapy

杂志名称： ACS Nano

作者： Wenjiao Cai,Yuelan Sun,Wenyue Xu, Xiuru Kuang,Zhe Zhang, Xiang Cao, Junyu Xu, Yi Li, Yongzhuo Huang,Shiyang Shen

IF: 16.1

The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer

杂志名称： Advanced Science

作者： Jiande Han, Hanlin Yin, Taochen He, Junyi He, Zhenlai Jiang, Qiangda Chen, Zhihang Xu, Yuqi Xie, Yaolin Xu, Haibo Wang, Wenquan Wang, Wenchuan Wu, Yun Jin, Wenhui Lou, Jun Yu, Ning Pu, Liang Liu

IF: 14.1

Selective depletion of CCR8+ Treg cells enhances the antitumor immunity of cytotoxic T cells in lung cancer by dendritic cells

杂志名称： J Thorac Oncol

作者： P Chen, H Wang, Z Tang, J Shi, L Cheng… - Journal of Thoracic …, 2025 - Elsevier

IF: 20.8